newsfilter
← Latest News
ACCESS Newswire·

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research clinical trial -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Raised